Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Albireo Pharma Inc (ALBO)

Albireo Pharma Inc (ALBO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of 10% and 1.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AGLE : 12.01 (+8.79%)
ALBO : 44.15 (-0.23%)
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Tops Revenue Estimates

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 86.67% and 16.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

DNA : 0.9881 (+3.47%)
ALBO : 44.15 (-0.23%)
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?

Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MIRM : 26.39 (+2.13%)
ALBO : 44.15 (-0.23%)
Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?

Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

ALBO : 44.15 (-0.23%)
LNTH : 75.51 (-0.03%)
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 21.13% and 9.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ALNY : 151.22 (-0.73%)
ALBO : 44.15 (-0.23%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TIG, ALBO, PAYA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TIG : 6.16 (+0.16%)
ALBO : 44.15 (-0.23%)
PAYA : 9.74 (+0.10%)
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -5.26% and 2.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for...

DCPH : 25.37 (-0.04%)
ALBO : 44.15 (-0.23%)
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

AQUA : 49.88 (+0.95%)
LPTX : 3.22 (+0.94%)
CNCE : 8.37 (+0.12%)
ALBO : 44.15 (-0.23%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALBO, CNCE, AQUA, LPTX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

ALBO : 44.15 (-0.23%)
CNCE : 8.37 (+0.12%)
AQUA : 49.88 (+0.95%)
LPTX : 3.22 (+0.94%)
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

AQUA : 49.88 (+0.95%)
LPTX : 3.22 (+0.94%)
CNCE : 8.37 (+0.12%)
ALBO : 44.15 (-0.23%)

Barchart Exclusives

After Its Historic Dividend Cut, Is 3M Stock Still Worth Buying?
3M stock is a Dividend King no more, as the company slashed its payout following the Solventum spinoff. Is the stock still a buy for investors seeking passive income? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar